Abstract
While the role of nuclear transcription factor activator protein-1 (AP-1) in cell proliferation, and of nuclear factor-κB (NF-κB) in the suppression of apoptosis are known, their role in survival of prostate cancer cells is not well understood. We investigated the role of NF-κB and AP-1 in the survival of human androgen-independent (DU145) and -dependent (LNCaP) prostate cancer cell lines. Our results show that the faster rate of proliferation of DU145 cells when compared to LNCaP cells correlated with the constitutive expression of activated NF-κB and AP-1 in DU-145 cells. The lack of constitutive expression of NF-κB and AP-1 in LNCaP cells also correlated with their sensitivity to the antiproliferative effects of tumor necrosis factor (TNF). TNF induced NF-κB activation but not AP-1 activation in LNCaP cells. In DU145 cells both c-Fos and c-Jun were expressed and treatment with TNF activated c-Jun NH2-terminal kinase (JNK), needed for AP-1 activation. In LNCaP cells, however, only low levels of c-Jun was expressed and treatment with TNF minimally activated JNK. Treatment of cells with curcumin, a chemopreventive agent, suppressed both constitutive (DU145) and inducible (LNCaP) NF-κB activation, and potentiated TNF-induced apoptosis. Curcumin alone induced apoptosis in both cell types, which correlated with the downregulation of the expression of Bcl-2 and Bcl-xL and the activation of procaspase-3 and procaspase-8. Overall, our results suggest that NF-κB and AP-1 may play a role in the survival of prostate cancer cells, and curcumin abrogates their survival mechanisms.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- AP-1:
-
activator protein-1
- CHX:
-
cycloheximide
- EMSA:
-
electrophoretic mobility shift assay
- FBS:
-
fetal bovine serum
- NF-κB:
-
nuclear transcription factor-κB
- IκB:
-
inhibitory subunit of NF-κB
- JNK:
-
c-jun N-terminal kinase
- MTT:
-
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
- PARP:
-
poly (ADP-ribose) polymerase
- PI:
-
propidium iodide
- TNF:
-
tumor necrosis factor, SEAP, secretory alkaline phosphatase
References
Abreu-Martin MT, Chari A, Palladino AA, Craft NA, Sawyers CL . 1999 Mol. Cell. Biol. 19: 5143–5154
Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott P . 1999 J. Cancer Res. 59: 2615–2622
Aggarwal BB . 2000 Biochem. Pharmacol. 60: 1033–1039
Ahmed MM, Sells SF, Venkatasubbarao K, Fruitwala SM, Muthukkumar S, Harp C, Mohiuddin M, Rangnekar VM . 1997 J. Biol. Chem. 272: 33056–33061
Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dorken B . 1997 J. Clin. Invest. 100: 2961–2969
Beg AA, Baltimore D . 1996 Science 274: 782–784
Chaturvedi MM, Mukhopadhyay A, Aggarwal BB . 2000 Methods Enzymol. 319: 585–602
Chen HW, Huang HC . 1998 Br. J. Pharmacol. 124: 1029–1040
Chen YR, Tan TH . 1998 Oncogene 17: 173–178
Colotta F, Polentarutti N, Sironi M, Mantovani A . 1992 J. Biol. Chem. 267: 18278–18283
Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Sawyers CL . 1999a Cancer Res. 59: 5030–5036
Craft N, Shostak Y, Carey M, Sawyers CL . 1999b Nat. Med. 5: 280–285
Darnay B, Ni J, Moore PA, Aggarwal . 1999 J. Biol. Chem. 274: 7724–7731
Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK, Steck PA . 1999 Cancer Res. 59: 2551–2556
Degeorges A, Wang F, Frierson Jr HF, Seth A, Chung LW, Sikes RA . 1999 Cancer Res. 59: 2787–2790
Dixit VM, Marks RM, Sarma V, Prochownik EV . 1989 J. Biol. Chem. 264: 16905–16909
Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, Barrett JC, Isaacs WB . 1995 Cancer Res. 55: 4813–4817
Giri DK, Aggarwal BB . 1998 J. Biol. Chem. 273: 14008–14014
Haridas V, Darnay BG, Natarajan K, Heller R, Aggarwal BB . 1998 J Immunol. 160: 3152–3162
Herrmann JL, Menter DG, Beham A, von Eschenbach A, McDonnell TJ . 1997a Exp. Cell. Res. 234: 442–451
Herrmann JL, Beham AW, Sarkiss M, Chiao PJ, Rands MT, Bruckheimer EM, Brisbay S, McDonnell TJ . 1997b Exp. Cell. Res. 237: 101–109
Herrmann JL, Briones Jr F, Brisbay S, Logothetis CJ, McDonnell TJ . 1998 Oncogene 17: 2889–2899
Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M . 1999 Mol. Cell. Biol. 19: 2690–2698
Huang TS, Lee SC, Lin JK . 1991 Proc. Natl. Acad. Sci. USA 88: 5292–5296
Jiang MC, Yang-Yen HF, Yen JJ, Lin JK . 1996 Nutr. Cancer 26: 111–120
Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, Sartor RB . 1999 J. Immunol. 163: 3474–3483
Kadkol SS, Brody JR, Pevsner J, Bai J, Pasternack GR . 1999 Nat. Med. 5: 275–279
Karin M, Liu Z, Zandi E . 1997 Curr. Opin. Cell. Biol. 9: 240–246
Kawamori T, Lubet R, Steele VE, Kelloff GJ, Kaskey RB, Rao CV, Reddy BS . 1999 Cancer Res. 59: 597–601
Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP . 1998 Cancer Res. 58: 3344–3352
Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB . 1998 Biochem. Pharmacol. 55: 775–783
Kumar A, Aggarwal BB . 1999 Meth. Enzymol. 300: 339–345
Kuo ML, Huang TS, Lin JK . 1996 Biochim. Biophys. Acta. 1317: 95–100
Li CJ, Zhang LJ, Dezube BJ, Crumpacker CS, Pardee AB . 1993 Proc. Natl. Acad. Sci. USA 90: 1839–1842
Lin J, Adam RM, Santiestevan E, Freeman MR . 1999 Cancer Res. 59: 2891–2897
Liu XH, Yao S, Kirschenbaum A, Levine AC . 1998 Cancer Res. 58: 4245–4249
McConkey DJ, Greene G, Pettaway CA . 1996 Cancer Res. 56: 5594–5599
Manna SK, Zhang HJ, Yan T, Oberley LW, Aggarwal BB . 1998 J. Biol. Chem. 273: 13245–13254
Mehta K, Pantazis P, McQueen T, Aggarwal BB . 1997 Anticancer Drugs 8: 470–481
Miyamoto S, Verma IM . 1995 Adv. Cancer Res. 66: 255–292
Miyamoto S, Chiao PJ, Verma IM . 1994 Mol. Cell. Biol. 14: 3276–3282
Nalca A, Qiu SG, El-Guendy N, Krishnan S, Rangnekar VM . 1999 J. Biol. Chem. 274: 29976–29983
Parker SL TT, Bolden S, Wingo PA . 1997 J. Clin. 46: 5–27
Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S, Howells L . 1999 Oncogene 18: 6013–6020
Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR . 1991 Nature 353: 670–674
Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R . 1995 O. Cancer Res. 55: 4438–4445
Ripple MO, Henry WF, Schwarze SR, Wilding G, Weindruch R . 1999 J Natl. Cancer Inst. 91: 1227–1232
Singh S, Aggarwal BB . 1995 J. Biol. Chem. 270: 24995–25000
Sintich SM, Steinberg J, Kozlowski JM, Lee C, Pruden S, Sayeed S, Sensibar JA . 1999 Prostate 39: 87–93
Sumitomo M, Tachibana M, Nakashima J, Murai M, Miyajima A, Kimura F, Hayakawa M, Nakamura H . 1999 J. Urol. 161: 674–679
Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, Mizuno T, Tohyama M . 1999 J. Biol. Chem. 274: 8531–8538
Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM . 1996 Science 274: 787–789
van Brussel JP, van Steenbrugge GJ, Romijn JC, Schroder FH, Mickisch GH . 1999 Eur. J. Cancer 35: 664–671
Wang CY, Mayo MW, Baldwin Jr AS . 1996 Science 274: 784–787
Acknowledgements
This research was conducted with support from The Clayton Foundation for Research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D. et al. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20, 7597–7609 (2001). https://doi.org/10.1038/sj.onc.1204997
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204997
Keywords
This article is cited by
-
Bioactive nutraceuticals as G4 stabilizers: potential cancer prevention and therapy—a critical review
Naunyn-Schmiedeberg's Archives of Pharmacology (2023)
-
Delivery of curcumin within emulsome nanoparticles enhances the anti-cancer activity in androgen-dependent prostate cancer cell
Molecular Biology Reports (2023)
-
Self-assembled fluorescent hybrid nanoparticles-mediated collaborative lncRNA CCAT1 silencing and curcumin delivery for synchronous colorectal cancer theranostics
Journal of Nanobiotechnology (2021)
-
Potential enhancement of host immunity and anti-tumor efficacy of nanoscale curcumin and resveratrol in colorectal cancers by modulated electro- hyperthermia
BMC Cancer (2020)